A preliminary analysis in the study shows that payers might be able to save between $38 million and $63 million per 100,000 members by focusing on patients with three or more overlapping chronic conditions.
CVS Pharmacy & Business News
For Americans who have ever gotten a flu shot, fall months are the most popular time to get the vaccine, with October being the most popular month (42%).
In addition to Idaho, CVS Pharmacy locations in 30 other states can dispense naloxone to patients without an individual prescription.
CVS Pay – now part of the CVS Pharmacy mobile app – integrates payment, prescription pickup and the ExtraCare loyalty program all in one quick scan at checkout.
USA Today is reporting that CVS Health has announced plans to remove two biologic drugs, Neupogen and Lantus, from its pharmacy benefits manager (PBM) formulary in 2017 and replace them with biosimilars of the drugs, substituting Zarxio for Neupogen and Basaglar for Lantus. Biosimilars cost about 15% to 30% less than the original biologics. CVS’s EVP and chief medical officer Troyen Brennan told USA Today that the biologics were reviewed by panels of experts “to make sure they are considered equivalent. (USA Today)
In this report, DSN examines sales activity in the healthy snack category, highlighting new products that are shaking up the consumables aisle.
More vitamins, minerals and supplements were sold online so far in 2016 than have been sold through a Walmart store, TABS Analytics reported earlier this year.
Health care is taking up a larger share of the consumer wallet. By 2021, Americans are expected to devote 24% of all household spending on healthcare goods and services, making consumer-directed care one of the largest potential areas of growth for retailers.
As millennials have cemented themselves as the largest generation by population at 75.4 million, outnumbering baby boomers for the first time, the retail industry has been inundated with insights about their shopping habits.
Based on second-quarter performance, CVS Health is raising and narrowing its Adjusted EPS guidance and also raising its free cash flow guidance for 2016.